Certified by Founder Lodge
Athernal Bio
United Kingdom - Cambridge
START UP
1 Disclosed Funding Rounds $4,718,630
0 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Developing targeted immunotherapies to treat high-risk clonal haematopoiesis (CH)—the precursor to blood cancers—so we can stop cancer before it starts.
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| October, 02 ,2025 | Unknown | $4,718,630 |
Delin Ventures
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
FOVC | $2,000,000 | (Jan 16, 2026)
CYB3R OPERATIONS | $5,400,000 | (Jan 16, 2026)
Project Eleven | $20,000,000 | (Jan 16, 2026)
depthfirst | $40,000,000 | (Jan 16, 2026)
Quadric | $30,000,000 | (Jan 16, 2026)
